Which Pharma Stocks Face the Biggest Patent Cliff?
Published April 6, 2026 · SEC filings, USPTO patent data & analyst estimates
The 2026-2030 patent cliff will reshape pharmaceutical valuations. Over $200 billion in annual drug revenue faces generic and biosimilar competition in the next five years. For investors, the critical question is not just which companies are most exposed, but which ones have the pipeline and strategy to replace lost revenue. Here is a company-by-company breakdown.
Revenue Exposure by Company
The following table shows the major pharmaceutical companies facing the largest patent cliffs, their key drugs at risk, estimated revenue exposed, and the timeline for patent expiration.
| Company | Key Drugs at Risk | Est. Revenue Exposed | Cliff Timeline |
|---|---|---|---|
| Merck | Keytruda | $25B | 2028-2029 |
| AbbVie | Humira (biosimilar erosion), Imbruvica | $18-22B | 2023-2028 |
| Bristol-Myers Squibb | Eliquis, Opdivo | $20-22B | 2026-2029 |
| Pfizer | Multiple mid-size drugs | $10-15B | 2026-2030 |
| Johnson & Johnson | Stelara, Darzalex | $15-18B | 2025-2029 |
| Eli Lilly | Trulicity, Verzenio | $8-10B | 2027-2030 |
Company-by-Company Analysis
Merck: The Keytruda Question
Merck faces the single largest product-level patent cliff in pharmaceutical history. Keytruda (pembrolizumab), the PD-1 checkpoint inhibitor, generated approximately $25 billion in 2025 revenue, representing roughly 45% of Merck total pharmaceutical sales. Key patents begin expiring in 2028, with biosimilar entry expected by 2029.
Merck strategy has been aggressive M&A and internal pipeline development. The $11 billion Prometheus Biosciences acquisition, the Daiichi Sankyo ADC partnership, and expanded oncology combinations are all designed to build a revenue bridge. However, replacing $25 billion from a single product is historically unprecedented.
AbbVie: Post-Humira Transition
AbbVie is already living through its patent cliff. Humira biosimilars entered the US market in 2023, and AbbVie has been executing a deliberate transition to Skyrizi and Rinvoq in immunology. Combined revenue from these two drugs is projected to exceed $27 billion by 2027, largely offsetting Humira erosion. However, Imbruvica (oncology) faces its own patent cliff in the late 2020s, adding a second wave of exposure.
Bristol-Myers Squibb: Double Exposure
Bristol-Myers Squibb may be the most vulnerable major pharma company. Eliquis (blood thinner, ~$12B revenue) and Opdivo (cancer immunotherapy, ~$9B revenue) both face patent expirations in the 2026-2029 window. Together, these two drugs represent over 40% of company revenue. BMY pipeline, while active in oncology and immunology, does not yet have a clear blockbuster replacement at Eliquis scale.
Johnson & Johnson: Stelara Cliff
Stelara (ustekinumab), J&J blockbuster immunology drug at roughly $10 billion in annual sales, lost key US patent protection in 2025 with biosimilars launching. Darzalex (daratumumab) in multiple myeloma provides a growth offset at ~$10 billion in revenue but will face its own biosimilar competition later in the decade.
Eli Lilly: Best Positioned
Among major pharma companies, Eli Lilly is widely considered the best positioned to weather the patent cliff. While Trulicity faces competition and patent expiration, Lilly GLP-1 receptor agonist franchise (tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity) is projected to generate $40-50 billion or more in peak revenue. This growth more than offsets any patent expirations in the existing portfolio.
Patent Portfolio Data
Our patent database tracks expiration timelines for major pharma companies. The following data shows patents expiring within the next 5 years for tracked pharmaceutical firms.
| Company | Total Patents | Expiring Within 5 Years | Strength Grade |
|---|---|---|---|
| Johnson & Johnson | 55 | 8 | D |
| Novartis | 55 | 8 | D |
| Roche | 52 | 9 | D |
| Pfizer | 50 | 9 | D |
| Merck | 48 | 11 | D |
| AbbVie | 48 | 2 | D |
| AstraZeneca | 48 | 6 | D |
| Eli Lilly | 45 | 4 | D |
| Sanofi | 45 | 4 | D |
| Bristol-Myers Squibb | 42 | 8 | D |
Strategies Companies Use to Manage the Cliff
Pharma companies deploy several strategies to mitigate patent cliff impact:
- Pipeline replacement: Developing or acquiring next-generation drugs in the same therapeutic area. AbbVie transition from Humira to Skyrizi/Rinvoq is the textbook example.
- M&A: Acquiring companies with late-stage or recently launched drugs. Pfizer $43 billion Seagen acquisition and Merck oncology-focused deals aim to rebuild revenue post-cliff.
- Lifecycle management: Filing new patents on formulations, delivery devices, or combination therapies to extend effective exclusivity. Merck subcutaneous Keytruda formulation is a current example.
- Authorized generics: Launching their own generic version on patent expiration day to capture generic market share and slow revenue erosion.
- Geographic expansion: Pushing into emerging markets where patent expirations may follow different timelines and biosimilar competition is less intense.
Investment Implications
For investors, the patent cliff creates both risk and opportunity. Companies trading at low multiples due to cliff concerns may be undervalued if their pipeline delivers. Conversely, companies priced for pipeline success face steep downside if clinical trials fail.
The key metrics to watch: replacement revenue trajectory (are new drugs growing fast enough?), pipeline clinical trial readouts (binary events that can shift the narrative), and free cash flow sustainability (can the company fund dividends and buybacks through the transition?). For a broader view of the timeline, see the full 2026-2030 patent cliff analysis. To understand which companies have the deepest moats, see companies with the strongest patent portfolios.
Frequently Asked Questions
Which pharma company has the biggest patent cliff?
Merck faces the single largest patent cliff with Keytruda, its cancer immunotherapy generating approximately $25 billion in annual revenue, losing key patent protection in 2028. Bristol-Myers Squibb also faces severe exposure with both Eliquis ($12B) and Opdivo ($9B) losing protection in the same timeframe. In dollar terms, these two companies have the most revenue at risk from the 2026-2030 patent cliff.
How does patent expiration affect stock price?
Patent expirations are typically priced into pharma stocks years before the actual expiration date. Markets begin discounting future revenue loss 3-5 years ahead. The stock impact depends on whether the company has pipeline drugs to replace lost revenue. Companies with strong replacements (like Eli Lilly with GLP-1 drugs) see minimal impact, while those without clear replacements (like Bristol-Myers Squibb) often trade at depressed multiples reflecting the cliff.
Are pharma stocks risky because of the patent cliff?
The patent cliff is a known risk that is already partially reflected in valuations. Pharma companies with large patent cliffs typically trade at lower price-to-earnings ratios, which means some of the risk is priced in. The real investment risk is whether pipeline replacements succeed or fail. A late-stage clinical trial failure at a company already facing a patent cliff can trigger steep declines. Diversified pharma companies with multiple growth drivers tend to weather cliffs better than single-product dependent firms.
Which pharma companies have the strongest pipeline to replace lost revenue?
Eli Lilly is widely considered best positioned, with tirzepatide (Mounjaro/Zepbound) for diabetes and obesity potentially generating $50+ billion in peak revenue. AbbVie has successfully transitioned much of its Humira revenue to Skyrizi and Rinvoq in immunology. Merck is investing heavily in oncology pipeline assets and acquisitions to offset the Keytruda cliff. AstraZeneca has built a deep oncology pipeline through internal development and acquisitions like Seagen.
About This Data
Revenue estimates from SEC 10-K filings and analyst consensus. Patent data from USPTO PatentsView API. Patent cliff timelines reflect key composition-of-matter and method-of-use patent expirations. See our methodology.